ReviewPediatric nephrology (Berlin, Germany)2025
Childhood idiopathic nephrotic syndrome: recent advancements shaping future guidelines.
Review in Pediatric nephrology (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Kidney Survival in Children With Steroid-Resistant Nephrotic Syndrome Treated by Rituximab.Kidney international reports · 2026Article
- Infection prophylaxis following anti-CD20 monoclonal antibodies in childhood kidney diseases.Pediatric nephrology (Berlin, Germany) · 2026Review
- Pandemic-Related Reductions in Respiratory Infections and New-Onset Nephrotic Syndrome: A Multicenter Cohort Study in Japan.Kidney medicine · 2026Article
- Beyond the Steroid Trial: A Scoping Review of Biomarkers for Pediatric Nephrotic Syndrome.Medical sciences (Basel, Switzerland) · 2026Article
- Efficacy and Safety of Rituximab Therapy to Sustain Remission in Young Children With Childhood Nephrotic Syndrome.Kidney international reports · 2026Article
- Nephrotic Syndrome: Current Management.Indian journal of pediatrics · 2026Review
- An Integrated Population Pharmacokinetic and Machine Learning Model for Predicting Tacrolimus Exposure in Adult Patients with Nephrotic Syndrome.Drug design, development and therapy · 2026Article
- Article
- Article
- Low-dose obinutuzumab for steroid-dependent nephrotic syndrome complicated by recurrent rituximab-induced serum sickness and anti-rituximab antibodies.Pediatric nephrology (Berlin, Germany) · 2025Article
- Epidemiology of Pediatric Nephrotic Syndrome: Real-World Data from Brazil.Glomerular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Childhood idiopathic nephrotic syndrome is an important pediatric kidney disease associated with significant morbidities and even mortality. Several guidelines have been developed to standardize the terminology and patient care among the pediatric nephrology community. Since the publication of these guidelines, there have been major breakthroughs in the disease management and the understanding of underlying pathogenesis through multi-omics investigations, including the identification of anti-nephrin autoantibodies, genetic susceptibility loci, and the pathogenic role of B cell subsets. In this educational review, we summarize the recent major advancements in idiopathic nephrotic syndrome and attempt to provide potential therapeutic approaches in both steroid-sensitive and steroid-resistant nephrotic syndrome that may shape future guideline development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.